Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790682 | 0.94 | LMNA (0.44) | POLBCYP3A4NPC1ALDH1A1MAPT | |
| SCHEMBL14948208 | 0.90 | POLB (0.45) | POLBCYP3A4NPC1ALDH1A1MAPT | |
| SCHEMBL3201584 | 0.89 | SIRT3 (0.47) | POLBCYP3A4NPC1ALDH1A1MAPT | |
| SCHEMBL14407244 | 0.88 | POLB (0.43) | POLBCYP3A4NPC1ALDH1A1MAPT | |
| SCHEMBL13379278 | 0.88 | POLB (0.43) | POLBCYP3A4NPC1ALDH1A1MAPT | |
| SCHEMBL14073384 | 0.87 | TSHR (0.48) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL14405897 | 0.85 | ALDH1A1 (0.39) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL4885683 | 0.84 | HTT (0.42) | POLBCYP3A4NPC1ALDH1A1MAPT | |
| SCHEMBL27119473 | 0.84 | SIRT3 (0.46) | POLBCYP3A4NPC1ALDH1A1MAPT | |
| SCHEMBL826033 | 0.84 | HTT (0.42) | POLBCYP3A4NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782482-B2 | Transdermal device for the controlled administration of at least one active ingredient to a patient | Therascape (FR) | 2017-10-10 | — | — | US | claimed |
| US-20050282239-A1 | Cell-permeable enzyme activation reporter that can be loaded in a high throughput and gentle manner | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-22 | — | — | US | claimed |
| US-20050148031-A1 | Catalytic efficiency and/or specificity of non-native substrates of enzymes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-07 | — | — | US | claimed |
| CN-110655585-A | Synthetic polypeptides and uses thereof | 中央研究院 | 2020-01-07 | — | — | CN | disclosed |
| US-9782482-B2 | Transdermal device for the controlled administration of at least one active ingredient to a patient | Therascape (FR) | 2017-10-10 | — | — | US | disclosed |
| US-9574189-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2017-02-21 | — | — | US | disclosed |
| US-9463248-B2 | Material, method for preparing same, and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2016-10-11 | — | — | US | disclosed |
| US-9463248-B2 | Material, method for preparing same, and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2016-10-11 | — | — | US | disclosed |
| EP-3000836-A1 | PHOTODEGRADABLE CROSSLINKING AGENT, PHOTODEGRADABLE GEL, CELL CULTURE DEVICE, CELL ARRANGEMENT/SEPARATION DEVICE, CELL ARRANGEMENT METHOD, CELL SEPARATION METHOD, METHOD OF FORMING TISSUE MATERIAL, AND TISSUE MATERIAL | National Institute of Advanced Industrial Science and Technology (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-20150057374-A1 | MATERIAL, METHOD FOR PREPARING SAME, AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-02-26 | — | — | US | disclosed |
| US-20150057374-A1 | MATERIAL, METHOD FOR PREPARING SAME, AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-02-26 | — | — | US | disclosed |
| EP-1588173-B1 | AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS | NOVO NORDISK AS (DK) | 2008-11-26 | — | — | EP | disclosed |
| US-7422855-B2 | Multiplexing assays for analyte detection | PERKINELMER LAS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080194537-A1 | Compounds Modifying Apoptosis | 2CUREX (DK) | 2008-08-14 | — | — | US | disclosed |
| EP-1888619-A2 | COMPOUNDS MODIFYING APOPTOSIS | 2cureX ApS (DK) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006128455-A2 | COMPOUNDS MODIFYING APOPTOSIS | 2CUREX APS (DK) | 2006-12-07 | — | — | WO | disclosed |
| US-20060003366-A1 | Multiplexing assays for analyte detection | PERKINELMER LAS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-20050282239-A1 | Cell-permeable enzyme activation reporter that can be loaded in a high throughput and gentle manner | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-22 | — | — | US | disclosed |
| EP-1200461-A2 | POLYPEPTIDE DENDRIMERS AS UNIMOLECULAR CARRIERS OF DIAGNOSTIC IMAGING CONTRAST AGENTS, BIOACTIVE SUBSTANCES AND DRUGS | Les Laboratoires Servier (FR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001007469-A2 | POLYPEPTIDE DENDRIMERS AS UNIMOLECULAR CARRIERS OF DIAGNOSTIC IMAGING CONTRAST AGENTS, BIOACTIVE SUBSTANCES AND DRUGS | LES LABORATOIRES SERVIER (FR) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194537-A1 | Compounds Modifying Apoptosis | API5, BAX, BAD | POLB 1772/4885CYP3A4 4747/4885NPC1 3483/4885 |
| US-20150057374-A1 | MATERIAL, METHOD FOR PREPARING SAME, AND USES THEREOF | H1-2, H1-0, LIPA | POLB 2279/4885CYP3A4 2716/4885NPC1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.